Coeptis strengthens measures to protect
shareholder interests through ShareIntel's investigation and due
diligence services
WEXFORD,
Pa., Feb. 7, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced the Company has retained
Shareholder Intelligence Services, LLC ("ShareIntel") for a
12-month, full-service agreement to review the trading patterns of
the Company's common stock; monitor, identify and reconcile
discrepancies; and target illegal short selling activities.
ShareIntel gathers and analyzes shareholder trading data through
its DRIL-DownTM process, a technology platform that
examines equity flows and reveals suspicious, aberrant, and/or
unusual trading activity. The tool aims to help management to
identify, interpret and communicate shareholder and broker-dealer
movement to the market.
"We want to ensure that Coeptis is not the target of market
manipulation," said Dave Mehalick,
President and CEO of Coeptis. "ShareIntel's proprietary analytics
will identify reporting anomalies among market makers, banks,
broker-dealers and clearing firms as it tracks share ownership and
identifies suspicious trading activity."
David Wenger, President and Chief
Executive Officer of ShareIntel, stated, "We look forward to
helping Coeptis identify potential abusive and illegal naked short
selling. A company's most valuable currency is its stock and it is
important to protect shareholders from egregious trading
activities."
Shareholder Intelligence Services, LLC – (ShareIntel)
ShareIntel is an application service provider retained by public
companies to obtain, aggregate, track and analyze shareholder
trading information. This process is managed through a proprietary
patent pending web-based application known as the "Data Repository
Information Link" system DRIL-DownTM.
In addition to its core business, ShareIntel can provide
value-added custom consulting services to help client companies
maximize the utility of our analyses. ShareIntel is a part of the
$5 billion plus rapidly growing
Software-as-a-Service ("SaaS") industry.
The ShareIntel solution empowers the public company CEO's with
unique analytical tools to manage their investment bankers, legal
counsel, investor relations, shareholders and more. ShareIntel
creates meaningful hard and soft dollar savings by providing
"instant" and actionable analytic metrics to coordinate and monitor
corporate governance, regulatory compliance, corporate finance, due
diligence, public offering market surveillance, mergers,
acquisitions, investor relations, shareholder communications, blue
sky compliance, road show planning and more.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics, Inc. and Coeptis
Pharmaceuticals, Inc., (collectively "Coeptis"), is a
biopharmaceutical company developing innovative cell therapy
platforms for cancer that have the potential to disrupt
conventional treatment paradigms and improve patient outcomes.
Coeptis' product portfolio and rights are highlighted by a
universal, multi-antigen CAR T technology licensed from the
University of Pittsburgh
(SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in
vitro diagnostic (CD38-Diagnostic) targeting CD38-related
cancers, which Coeptis is developing with VyGen-Bio and leading
medical researchers at the Karolinska Institutet. Coeptis' business
model is designed around maximizing the value of its current
product portfolio and rights through in-license agreements,
out-license agreements and co-development relationships, as well as
entering into strategic partnerships to expand its product rights
and offerings, specifically those targeting cancer. The Company is
headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Global Market following the business combination; (2) the risk that
the business combination disrupts current plans and operations of
Company as a result of the consummation of the business
combination; (3) the inability to recognize the anticipated
benefits of the business combination, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(4) the risks that the Company's products in development fail
clinical trials or are not approved by the U.S. Food and Drug
Administration or other applicable regulatory authorities; (5)
costs related to the business combination; (6) changes in
applicable laws or regulations; (7) the possibility that the
Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date hereof unless required by applicable laws,
regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy
Sr. VP of Communications
504-416-6965
andy.galy@coeptistx.com
Investors
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media
Bill Borden
732-910-1620
bborden@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-and-shareintel-enter-shareholder-service-agreement-targeting-illegal-short-selling-301740015.html
SOURCE Coeptis Therapeutics, Inc.